Prabhudas Lilladher's research report on Max Healthcare Institute
Max Healthcare Institute (MAXHEALT) reported EBITDA of Rs4.9bn (up 13% QoQ) which came 7% above our estimates, aided by healthy ARPOB at Rs.74.6k and better margins. The company showed phenomenal growth in past two years and we expect this momentum to continue given 1) strong expansion plans (+2000 additional beds over FY23-26E), 2) improving payor mix (15% revenue contribution from institutional by FY25E vs 17.9% now) and 3) scale-up in labs. Operational efficiency has also been commendable, especially in competitive markets like NCR. Our FY24E/25E EBITDA increased by 5%/4% and we expect 18% EBITDA CAGR over FY23-26E.
Outlook
We ascribe 26x EV/EBITDA based on Sept 2025E EBITDA. Maintain ‘BUY’ rating with revised target price of Rs. 675/share (Rs610 earlier) as we roll forward.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
